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Medical marijuana is increasingly prescribed as an analgesic for a growing number
of indications, amongst which terminal cancer and multiple sclerosis. However,
the mechanistic aspects and properties of cannabis remain remarkably poorly
characterized. In this study we aimed to investigate the immune-cell modulatory
properties of medical cannabis. Healthy volunteers were asked to ingest medical
cannabis, and kinome profiling was used to generate comprehensive descriptions of
the cannabis challenge on inflammatory signal transduction in the peripheral blood
of these volunteers. Results were related to both short term and long term effects in
patients experimentally treated with a medical marijuana preparation for suffering from
abdominal pain as a result of chronic pancreatitis or other causes. The results reveal
an immunosuppressive effect of cannabinoid preparations via deactivation of signaling
through the pro-inflammatory p38 MAP kinase and mTOR pathways and a concomitant
deactivation of the pro-mitogenic ERK pathway. However, long term cannabis exposure
in two patients resulted in reversal of this effect. While these data provide a powerful
mechanistic rationale for the clinical use of medical marijuana in inflammatory and
oncological disease, caution may be advised with sustained use of such preparations.
Keywords: kinome profiling, mTOR-S6, monocyte, T cells, inflammatory signaling
INTRODUCTION
Although cannabis, derived from the dried flower buds of the female plant of Cannabis sativa L.,
has been used in medicine for many centuries, the recent decade has seen an increased acceptance
of medical marijuana preparations for pain relief in a variety of inflammatory and oncological
conditions (Gerich et al., 2015). Cannabis has been used in clinical practice for its analgesic,
nausea-reducing and hunger-inducing properties and has recently been approved for treatment
of spasticity caused by multiple sclerosis (Wilson and Nicoll, 2002). Cannabis contains several
components, but its main psychoactive ingredient is 19–tetrahydrocannabinol (THC) (Howlett,
1995). Two cannabinoid receptors have been identified to date; CB1 and CB2 (Howlett, 1995),
in addition to which the orphan G-protein coupled receptor 55 was shown to be activated by
cannabinoids (Henstridge, 2012). CB1 is expressed both in the periphery and in structures of the
central nervous system, where it accounts for the main effects seen after cannabis use, including
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sedation, dizziness, confusion and somnolence (Barinaga, 2001).
Although CB2 receptors are also found and functional in the
central nervous system, CB2 is mainly considered a peripheral
cannabinoid receptor (Van Sickle et al., 2005). It is mostly found
on cells of the immune system and is therefore speculated
to play a part in immunoregulatory responses, although its
mechanistic aspects remain to be elucidated (Turcotte et al.,
2016).
Studies involving the potential role of cannabinoid receptors
in inflammatory disease have shown that activation of the
cannabinoid system can offer protection in experimental colitis
models by reducing inflammation (Massa et al., 2004; Klein,
2005). In cerulein-induced acute pancreatitis, administration
of cannabinoid agonists reduced inflammation and alleviated
pain in mice (Michalski et al., 2007). Follow up research
demonstrated that the addition of cannabinoids leads to
a reduced inflammatory and fibrotic profile in pancreatic
stellate cells in vitro (Michalski et al., 2008). Despite these
indications of an effect of THC on immunity, very little is
known of the direct immune modulatory effect of THC on
peripheral blood cell populations. Ex vivo THC treatment
reduces expression of cell surface receptors CD14, CXCR4 and
CCR5 on isolated monocytes, thereby limiting HIV infection
rate of these cells, but how cannabinoid receptor engagement
provokes these effects remains unexplored (Williams et al.,
2014). Mouse studies show that THC also exerts an effect on
adaptive immunity, through modulation of T cell differentiation
and reducing their interferon-γ production, but again the
underlying effects on T cell biology remain obscure and
require urgent clarification (Steffens et al., 2005; Karmaus et al.,
2013).
Further hampering understanding of the processes mediating
THC effects is the fact that although both CB1 and CB2 are Gi-
protein coupled receptors, in vitro studies in mast cells show
that these receptors mediate diametrically opposed effects on
downstream adenylate cyclase activity and cAMP levels and thus
the net effect of medical cannabis on signal transduction in vivo
remains unclear (Small-Howard et al., 2005). In neuronal cells,
cannabinoids were shown to decrease adenylate cyclase activity
and cAMP levels, and activate the PI3 kinase/Akt, p38MAP
kinase and ERK signaling cassettes, thereby modulating neuron-
specific ion channels (Chiurchiù et al., 2015). In peripheral
immune cells, however, activation of PI3 kinase/Akt, p38MAP
kinase and ERK are more associated with an inflammatory
response (van den Brink et al., 2000), whereas there appears to
be a consensus that the effects of medical cannabis are of an
anti-inflammatory nature (Mallat et al., 2013), suggesting that
cannabinoid signaling in non-neuronal cells may be markedly
different. Thus defining the action of medical cannabis on in vivo
signaling of human immune cells is now a pressing concern,
and essential for the design of novel rational cannabinoid
therapy.
The above-mentioned considerations prompted us to explore
the effects of medical marijuana using kinome profiling
(Fuhler et al., 2011; Hazen et al., 2011), revealing wide-spread
signaling effects of cannabis on peripheral blood mononuclear
cells.
MATERIALS AND METHODS
Collection of Human Materials and
Treatment With Medical Marijuana
Preparation
Patients suffering from chronic abdominal pain as a result of
chronic pancreatitis or postsurgical pain were recruited at the
Radboud University Medical Centre, Nijmegen, the Netherlands
(Supplementary Table S1). The pain was considered severe
enough for medical treatment, despite endoscopic, surgical
or medical interventions. This study was part of two phase
2 trials using identical randomized, double-blind, placebo-
controlled, parallel designs (clinicalTrials.gov ID: NCT01551511
and NCT01562483). For study controls unpaid cannabis-naïve
healthy volunteers were solicited from the medical school student
and employee population. For in vivo assessment of the effect
of THC, blood for measurements was collected in Li-heparin-
containing Vacutainer tubes (BD Vacutainer Systems, Plymouth,
U.K.) at 0 and 180 min relative to drinking 400 ml of a medicinal
cannabis preparation (Bedocran; Veendam, The Netherlands),
prepared by covered boiling of 1 g Bedrobinol in 1 L of
water for 15 min. For studies in patients, Namisol R© tablets
containing purified, natural and standardized THC content
were administered orally as add-on medication. The treatment
regimen consisted of 2 phases: a step-up phase and a stable
phase. In the step-up phase, patients received 3 mg Namisol R©
three times a day (TID) for the first 5 days. If this dose was
considered tolerable, the dose was increased on day 6 to 5 mg
TID, and if not, the patient was withdrawn. The same procedure
was conducted on day 9–10, tolerability was evaluated again
and if 5 mg TID dosage appeared tolerable for the patient, the
dosage was further increased to 8 mg TID from day 11. When
8 mg appeared to induce unacceptable adverse events, the dosage
was tapered to 5 mg TID. This dose was maintained up to
day 50–52 and was considered the stable phase. Blood samples
were acquired on day 0 predose, day 15 predose, day 50–52
at 4 timepoints (predose, 1, 3, and 5 h after intake). For the
graphic representation of the study design see Supplementary
Figure S4.
Peripheral Blood Mononuclear Cell
(PBMC) Isolation and Stimulation
Peripheral blood mononuclear cells were isolated using density
gradient centrifugation (Ficoll-Paque, GE Healthcare). Cells
were washed in PBS twice, and either used directly, or
resuspended in RMPI culture medium, supplemented with 10%
fetal bovine serum and penicillin/streptomycin for in vitro
stimulations. In vitro stimulations were performed in 96 wells
plates (Corning, Tewksbury, MA, USA), using 100 ng/mL
lipopolysaccharide (LPS, Sigma Aldrich, St Louis, MO, USA),
1.2 × 105 CD3/CD28 Dynabeads (Life Technologies, Carlsbad,
CA, USA) and/or 2 ng/ml pure THC (Echo pharmaceuticals,
Nijmegen, the Netherlands) for the indicated time points.
Concentration THC used was based on serum levels measured
in individuals 2 h after Namisol R© ingestion (de Vries et al.,
2016).
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Kinome Profiling
Kinome profiling was performed as described in (Fuhler et al.,
2011). PBMCs were lysed in ice-cold Pepchip cell lysis buffer
(20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM Na2EDTA,
1 mM EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate,
1 mM MgCl2, 1 mM µ-glycerophosphate, 1 mM Na3VO4,
1 mM NaF, 1 µg/ml leupeptin, 1 µg/ml aprotinin, 1 mM PMSF).
Samples were sonicated four times for 5 s on ice and centrifuged
at 7000 × g for 10 min at 4◦C. Protein content in the clear
supernatant was determined with a bicinchoninic acid protein
assay kit (Pierce, Rockford, IL, USA), using BSA as the standard,
and the supernatant was stored at −80◦C until peptide array
analysis.
For peptide array analysis, we employed the Pepchip kinomics
array, featuring 960 different human-only kinase substrate
peptides in addition to 70 positive and negative controls, each
spotted in triplicate. In short, the cell lysates were cleared by
centrifugation and peptide array incubation mix was produced
by adding 10 µl of activation mix (50% glycerol, 50 µM ATP,
0.05% v/v Brij-35, 0.25 mg/ml bovine serum albumin) and
2 µl [γ-33P] ATP (∼1000 kBq; Amersham AH9968). Next,
the peptide array mix was added onto the chip, and the
chip was kept at 37◦C in a humidified stove for 90 min.
Subsequently the peptide array was washed twice with Tris-
buffered saline with Tween 20, twice in 2 M NaCl, and twice
in demineralised H2O and then air-dried. The chips were
exposed to a phosphor screen for 72 h, and the density of
the spots was measured and analyzed with array software
(ScanAnalyze).
Statistical Analysis
The peptide array data analysis was done as described earlier
(Parikh et al., 2014). ScanAlyze software was used. Spot density
and individual background intensities were analyzed using
grid tools and data from three individual experiments, each
consisting of three technical replicates, were exported to an
excel sheet for further analysis. Means of spot intensity (i.e.,
kinase activity toward a specific substrate) were first subjected
to Markov state analysis (i.e., is the peptide significantly
more phosphorylated than background) and the reactions in
which this is the case are listed in Supplementary Table
S2, which also include other numerographic and biochemical
information on the data. These Markov scores were collapsed
on signal categories that provide insight into the difference
in signaling between the THC-stimulated and unstimulated
conditions.
Flow Cytometry
Cells were fixed using 2% paraformaldehyde/1% FCS/0.02%
EDTA in PBS and stored at 4◦C. Surface staining with
CD3-Amcyan (1:25; BD Biosciences, Breda, Netherlands) was
performed the next day. Next, the PBMCs were permeabilized
using a permeabilisation buffer (0.5% saponine, 1% FCS, 0.02%
EDTA in PBS) and subsequently stained intracellularly with V450
Mouse anti-phospho S6 (pS6) (1:20; BD Biosciences, Breda, the
Netherlands). Data was analyzed using FlowJo software (vX.0.6,
Treestar, Ashland, OR, USA).
Quantitative Western Blot Analysis
Immunoblotting of PBMC lysates was performed as described,
with some adjustments (Somasundaram et al., 2013). After
centrifugation, PBMCs were lysed in 2x Laemmli buffer (1%
Bromophenol blue, 1% dithiothreitol, 10% sodium dodecyl
sulfate, 1M Tris-Cl pH6.8) and boiled. Proteins were separated
by polyacrylamide gel electrophoresis, and gels were blotted
on Immobilon-FL transfer membrane (Millipore, Billerica,
MA, USA). Primary antibodies against phosphorylated forms
of p38, extracellular signal-regulated kinase (ERK), Protein
kinase B/AKT, NF-κB-p65 and p70S6 were from Cell Signaling
Technology (Beverly, MA, USA). Anti-rabbit or anti-mouse
IRDye-conjugated secondary antibodies were used according to
manufacturer’s directions, and blots were scanned by Odyssey
infrared imaging (LI-COR Biosciences, Lincoln, NE, USA).
Equal loading was confirmed by reprobing blots with β-actin
antibodies (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
Quantification was performed using Odyssey 3.0 software.
To calculate the relative pS6 levels, densitometry values of
phosphorylated proteins were divided by densitometry values of
the β-actin signal in the same lanes.
RESULTS
Kinome Profiling of
Lipopolysaccharide-Stimulated Blood
Demonstrates Inhibition of
Pro-inflammatory Signaling Following
Medical Cannabis Use
There is little insight into the action of medical cannabis on
signal transduction in human lymphocytes. Hence we asked three
healthy cannabis-naïve volunteers to drink a medicinal cannabis
preparation. Peripheral blood was obtained before and 2 h after
ingestion. In order to mimic the inflammatory state commonly
aﬄicting patients who are prescribed medicinal cannabis and
as kinome profiling is most useful to characterize effects in
potentiated signaling networks (Irish et al., 2004), blood was
stimulated ex vivo for 10 min with 100 ng/ml lipopolysaccharide,
followed by isolation of peripheral blood mononuclear cells
(PBMCs) which were immediately subjected to kinome profiling
(Diks et al., 2004). Kinome profiling constitutes an unbiased
approach to characterizing signal transduction and in our case
involves measuring the kinase activity toward 976 different
substrates. Kinome profiles obtained before and after medical
cannabis use were contrasted (Supplementary Figure S1 shows
untreated versus medicinal cannabis-treated peripheral blood
scatter plot where each dot represents the normalized mean
phosphorylation level for each of the 976 substrates arrayed).
As expected, there was a great deal of similarity between the
two phosphoproteomes (r2 = 0.88). However, a distinct subset
of substrates falls off the diagonal toward the after medicinal
cannabis axis (kinase activity stimulated by medicinal intake)
or to the before medicinal cannabis axis. In fact, we found that
phosphorylation of 124 substrates on the 976 peptide array differs
significantly between the two data sets. Thus our results form
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the first documentation that in vivo treatment with medical
cannabis acutely influences signal transduction in the human
PBMC compartment.
To obtain insight into the underlying effects, kinome results
were collapsed on elective signal transduction categories and
the potentiated kinome of cannabis unstimulated and stimulated
PBMCs was contrasted. Figure 1 shows the result and reveals
a plethora of effects evoked by medical cannabis in the PBMC
compartment. Generally speaking, G protein-coupled receptors
evoke activity of receptor kinases that desensitize subsequent
responses through β-arrestin-mediated mechanisms including
phosphorylation, internalization, and receptor degradation (Sato
et al., 2015). We observed strong induction of G protein-
coupled receptor kinase activity (denominated as beta-adrenergic
receptor kinase activity, Figure 1) following ingestion of
medical cannabis by our volunteers. Other prominent effects
include a downregulation of the pro-mitogenic kinase ERK
and according signs of impaired cell cycling, which fits well
with the anti-proliferative effects of cannabinoids on cancer
cells in vitro (Chakravarti et al., 2014). The most significant
effect, however, appeared to be a prominent downregulation
of pro-inflammatory signaling, in particular that mediated by
the stress-activated kinases p38MAP kinase and JNK, both
prominent mediators of inflammatory gene transcription whose
inhibition counteracts human inflammation in vivo, particularly
for innate immunity (Hommes et al., 2002; Branger et al., 2003).
In addition, deactivation of the PKB/mTOR signaling cascade
and Ca2+ signaling was observed, whose inhibition is powerful
in combating adaptive immune responses (e.g., in orthotopic
organ transplantation recipients). The results would thus support
the short-term use of medical marijuana in cancer (reduced
cell proliferation) and autoimmune disease (diminished pro-
inflammatory signaling).
Direct Effects of THC on the PBMC
Compartment
In our experimentation, drinking a medical cannabis preparation
provoked acute strong anti-inflammatory signaling in volunteers.
This set up of experimentation does not address, however,
if these effects are mediated by THC, generally assumed
to be the most potent bio-active compound in marijuana,
or some other plant constituent. Furthermore, effects of the
treatment can be the result of a direct effect on the PBMC
compartment, but may also have been the result of an indirect
effect mediated by secondary mediators, either neuronal or
non-neuronal. Hence, we wished to validate the observed
kinomic changes in vitro through another technique (Figure 2).
Therefore, PBMCs were isolated from THC naive healthy
subjects, pre-treated in vitro with 2ng/mL THC for 1 h and
stimulated with lipopolysaccharide (LPS) for 10 min. As shown
in Figure 2A, LPS effectively triggered phosphorylation of
p38MAPK, ERK, S6 and AKT in PBMCs. Pretreatment of cells
with THC significantly reduced these phosphorylation patterns
(Figure 2B). Consistent with kinome profiling results, no effect
of THC treatment was seen on p65 phosphorylation (indicating
NFκB signaling; Supplementary Figure S2). LPS-mediated
inflammatory signaling is directly reduced by interaction of
THC with immune cells, probably through engaging CB1/2
receptors.
Innate and Adaptive Immune Response
Require Different Signals
LPS is generally regarded as an agonist of innate immune cells,
most notably monocytes, with relatively little effect on adaptive
cells (Janssens and Beyaert, 2003). However, in light of the
potential effect of THC on T cells, we wanted to specifically
investigate the effect of THC on inflammatory T cell signaling
as well. To this end, we first confirmed innate and adaptive–
specific signaling in PBMCs through stimulation with LPS
and the T cell stimulus αCD3/CD28, respectively. Indeed, LPS
drastically enhanced p38 phosphorylation in PBMCs, with little
p38 activation seen upon αCD3/CD28 stimulation (Figure 3A).
In contrast, while S6 phosphorylation was observed upon LPS
stimulation, αCD3/CD28 was a much more efficient trigger of
S6 phosphorylation. Considering the fact that PBMCs are a
mixture of cells, the main constituents of which are monocytes
and T cells, we confirmed these findings by intracellular flow
cytometry of phospho-S6, allowing separate analysis of these
cell subsets (see Supplementary Figure S3 for gating strategy).
Figures 3B,C show that while LPS had little effect on S6
phosphorylation in CD3+ T cells, a robust stimulation of
pS6 was observed in response to αCD3/CD28 stimulation. As
constitutive S6 phosphorylation in monocytes was consistently
higher than in T cells, LPS-enhanced S6 phosphorylation
in this subset was more modest. Interestingly, αCD3/CD28
stimulation also resulted in S6 phosphorylation in monocytes,
suggesting that T cell products released upon αCD3/CD28
stimulation in the PBMC mixture are capable of activating
monocytes. These data suggest that while the innate pro-
inflammatory response requires p38 activity, both the innate and
adaptive immune responses are dependent on mTOR-p70S6-S6
signaling.
THC Decreases mTOR-S6 Signaling
Within CD3+ T Cells and Monocytes In
vitro
Our kinome data documents that the in vivo use of medicinal
cannabis downregulates potentiated mTOR pathway activation
in PBMCs, but leaves the cell types contributing to these
effects unresolved. We thus decided to further investigate the
effect of pure THC on the mTOR pathway in the different
immune cell subsets constituting the PBMC compartment. To
this end, isolated PBMCs of healthy volunteers were incubated
for 0, 1, or 3 h with 2 ng/ml pure THC. As shown in
Figures 4A,B, THC drastically reduces S6 phosphorylation
in CD3+ T cells. Again, constitutive phosphorylation of
S6 is higher in monocytes, and THC treatment results
in attenuated levels of pS6 in the latter subset as well,
although effects on the T cell compartment are much more
marked. Next, we investigated the effect of THC on LPS- or
αCD3/CD28-mediated S6 phosphorylation. Figure 4C shows
that THC reduces both LPS- and αCD3/CD28-mediated
Frontiers in Molecular Neuroscience | www.frontiersin.org 4 January 2017 | Volume 10 | Article 14
fnmol-10-00014 January 21, 2017 Time: 15:15 # 5
Utomo et al. Cannabis-Induced Stimulation of Immune Signaling
FIGURE 1 | Potentiated signal transduction in PBMCs before and after the intake of medical cannabis. Blood was drawn from three self-reported
cannabis-naive volunteers before and 2 h after the drinking of a medical cannabis preparation and stimulated for 10 min with lipopolysaccharide (100 ng/ml 10 min).
Subsequently PBMC were isolated and investigated using peptide arrays exhibiting 976 different kinase substrates. Results were collapsed on elective signal
transduction categories and expressed in gray scale (representing the fraction of peptides phosphorylated in either condition per pathway. White means no peptides
were significantly phosphorylated and black means all phosphorylated substrates were found in one of the conditions). Some of the most prominently affected signal
transduction elements have been highlighted in yellow. Note inhibition of pro-inflammatory signaling following medical cannabis use.
pS6 in whole PBMC fractions as determined by Western
blot analysis, which was qualitatively confirmed by separate
analysis of T cell and monocyte populations by intracellular
FACS analysis (Figure 4D). Thus medical cannabis acutely
impairs signaling mediating both innate and adaptive immunity
and thus our results would support the use of cannabis
for treating patients suffering from an exaggerated immune
response.
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FIGURE 2 | In vitro validation of direct THC effect on immune cells. PBMCs were isolated from healthy subjects (n = 6) and after in vitro pretreatment with
THC (2 ng/mL) for 1 h, cells were stimulated with 100 ng/mL lipopolysaccharide (LPS) for 10 min. Western blot analysis shows that unstimulated cells show relatively
little activation of p38MAPK, AKT, S6 or ERK, while LPS induces phosphorylation of these kinases. Pretreatment of PBMCs with THC significantly reduces
LPS-induced pro-inflammatory phosphorylation patterns. (A) Representative example is shown. (B) Quantification of phosphorylation levels of LPS-stimulated cells,
normalized for total Actin levels are shown. pS6 and pERK levels are significantly reduced upon THC treatment of cells (∗0.0357, ∗∗0.0238). Phosphorylation of p38
was reduced upon THC treatment in 5/6 subjects. pAKT was detectable in only four subjects, in three of which phosphorylation was reduced in THC treated cells.
Short Term Downregulation, But
Potential Long Term Upregulation of the
mTOR Pathway by THC in Patients
In vivo
Having seen a strong immunosuppressive signaling in T cells
and monocytes in vivo and in vitro in healthy subjects, we
wondered whether these findings would also be observed in
patients undergoing prolonged use of medicinal cannabis in the
course of their treatment. We therefore measured S6 activity by
intracellular FACS analysis in patients experimentally receiving
oral natural THC as a tablet (Namisol R©). Four patients were
included in the study for severe abdominal pain, resulting
from chronic pancreatitis (three patients) or repeat abdominal
surgeries (one patient). Details of dosing scheme can be
found in Supplementary Figure S4. Similar to our data in
healthy individuals, S6 phosphorylation levels in monocytes
and T cells drastically dropped within 1–5 h after intake
of THC (Figures 5A,B). For two patients, we were able to
collect longitudinal samples spanning the entire 50 days study
period, including a pre-dose sample. Interestingly, in these two
patients, we observed a very clear and constant increase in S6
phosphorylation in T cell compartment as well as in monocyte
compartment over time during the study (Figure 5C). This
increase in S6 phosphorylation remained, however, sensitive
to short term treatment with medical cannabis (evident 1–5 h
after intake of Namisol R©). Thus, from our in vitro and in vivo
data, the short term effects of THC include mTOR-S6 pathway
downregulation, also in patients in chronic high THC regimen
and thus in principle support use of medical cannabis for
the treatment of chronic inflammatory diseases. However, our
anecdotal evidence suggests that long term use of Namisol R©
may increase levels of mTOR activity in T cells and monocytes,
which indicates that the therapeutic dosing window for medical
cannabis to combat inflammatory disease requires careful
attention.
DISCUSSION
Medical marijuana is increasingly used to treat a variety of
inflammatory diseases, but there is a paucity of mechanistic
data that would support its use to combat inflammation per se
(Gerich et al., 2015). In addition, its use in oncological disease
is increasing, but again relatively little insight exists on how
cannabis might influence the cancerous process (Chakravarti
et al., 2014). Thus research characterizing these effects in
humans is urgently needed. In this study, we employed kinome
profiling to investigate the effect of medical marijuana on
immune cell signaling in potentiated PBMCs. Using this unbiased
approach (Li et al., 2012) we show that cannabis negatively
modulates inflammatory signaling in immunocytes in vivo,
and subsequent in vitro experimentation confirmed that these
effects most likely derive from THC effects. We demonstrate
that innate immune cell signaling is qualitatively, quantitatively
and temporally different from adaptive cell signaling, but that
phosphorylation of the immune signal S6 is decreased by
THC in both monocytes and T cells. It is possible that total
protein levels are affected by THC treatment, resulting in lower
phosphorylation patterns. Unfortunately, material availability
did not allow investigation of upstream mechanisms of S6
phosphorylation reduction. Signaling through mTOR-S6 in T
cells has a well-known pro-inflammatory character (Pollizzi
and Powell, 2015). However, in innate immune cells, mTOR-
S6 signaling has also been suggested to reduce inflammatory
responses (Weichhart and Säemann, 2009). Thus, the effect of
inhibition of mTOR-S6 signaling may not be clear-cut. However,
the overall effect appears to be a reduction of immunity, as
perhaps best demonstrated by the use of mTOR inhibitors,
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FIGURE 3 | Differential activation of immune signaling using monocyte or T cell –specific triggers. Whole PBMC fractions were stimulated with either LPS
(10 min) or αCD3/CD28 (10 min or 1h). (A) Western blot analysis shows that both stimuli induce a distinct set of phosphorylations. (B) Percentage of phospho-S6
positive cells as determined by intracellular FACS analysis, confirming that LPS does not trigger S6 phosphorylation in CD3+ T cells, whereas αCD3/CD28 generates
a robust response in this cell type. In contrast, lipopolysaccharide does stimulate S6 phosphorylation in monocytes, with αCD3/CD28 also eliciting a response.
(C) Representative example of FACS analysis of 4 independent experiments is shown.
such as the Rapamycin analogs Everolimus and Sirolimus, in
the prevention of organ rejection after transplantation (Gong
et al., 2015), although this may depend on the cell type
contributing most to the immunological process at hand.
Interestingly, HIV viral load was severely reduced in high-
intensity cannabis users, supporting an immunomodulatory or
antiviral effect of cannabinoids (Milloy et al., 2015). Altogether,
our data appear to provide mechanistic support for the
application of THC or cannabis preparations in the clinical
management of diseases with an inflammatory component.
However, it needs to be taken into account that whereas
in a clinical setting inflammatory signals may already be
present in patients newly receiving medicinal cannabis, in
the current study cells were treated with THC prior to LPS
stimulation, in order to obtain optimal potentiation of LPS
signals.
To the best of our knowledge, this is the first report showing an
acute downmodulation of mTOR-S6 signaling in immunocytes
by cannabinoids. mTOR signaling has been studied before in
response to cannabinoid receptor stimulation in other cell types,
with conflicting results. Effects may depend on the location of
receptor stimulation. CB1 and CB2 agonists increased mTOR-
S6 signaling in oligodendrocytes (Gomez et al., 2011) and CB1
stimulation by THC resulted in transient mTOR activity in the
brain (Puighermanal et al., 2009). In contrast, peripheral activity
of CB1 receptor stimulation results in reduced mTOR activity, as
was demonstrated by increased mTOR/S6K activation in gastric
cells upon application of the CB1 antagonist rimonabant (Senin
et al., 2013). This fits in with our finding of reduced mTOR
signaling in peripheral blood cells upon cannabis application and
thus the mechanistic insights obtained in the experimentation in
volunteers and patients appear to have a more general relevance.
While we focused mainly on the anti-inflammatory molecular
consequences of THC treatment of peripheral blood cells,
mediated through p38 MAPK and mTOR-S6 signaling, several
other interesting kinomic changes were observed upon cannabis
intake in this study. For instance, a significant reduction of Wnt
signaling was seen in potentiated PBMCs upon THC exposure.
Wnt signaling is not only important for the regulation of
embryogenesis, but also plays a role in cellular proliferation,
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FIGURE 4 | THC reduces S6 phosphorylation in T cells and monocytes. (A) Basal levels of S6 phosphorylation were determined by intracellular flow cytometry.
S6 phosphorylation was reduced in monocytes and T cells upon in vitro treatment of cells with THC for 1 or 3 h. (B) Mean percentage of pS6 positive CD3+T cells
(upper panel) and monocytes (lower panel) of six independent experiments. (C) Whole PBMC fractions were pretreated in vitro with THC for 1h or left untreated, and
subsequently stimulated with either LPS (10 min) or αCD3/CD28 (1 h). THC pretreated samples show less S6 phosphorylation upon LPS or αCD3/CD28 stimulation
(representative example of 6 experiments is shown). (D). FACS analysis of LPS (10 min) or αCD3/CD28 (1 h) stimulated PBMCs, gated on monocyte and T cell
fractions, respectively. Mean of four independent experiments is shown.
FIGURE 5 | Intake of THC reduces S6 phosphorylation in patient PBMCs in the short term, but enhances S6 phosphorylation in the long term.
(A) PBMCs were isolated from patients taking medicinal marijuana for pain-related complaints for 52 days. On day 52, samples were obtained pre-dose, and 1, 3,
and 5 h after THC intake. A representative example of n = 4 is shown, demonstrating that the short term effects of THC intake include a decrease in S6
phosphorylation. (B) Mean percentage pS6 positive T cells and monocytes (n = 4). (C) For two patients, PBMCs were isolated pre-dosing on day 0, day 15 and day
52, as well as post-dose on day 52. Both patients show a clear increase of S6 phosphorylation during prolonged THC treatment, which is decreased upon short
term treatment.
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migration and differentiation (van den Brink et al., 2004; Arias
and Hayward, 2006). The Wnt signaling cascade has gained
notoriety due to its deregulated nature in many cancers, where
it is now regarded as target for treatment (Zhang and Hao,
2015). However, recent evidence suggests that Wnt may also
regulate inflammation, in particularly by stimulating innate
immunological responses, and aberrant activity and increased
signaling is found in inflammatory disorders (George, 2008;
Clevers and Nusse, 2012). Interestingly, while endogenous
cannabinoids inhibit Wnt signaling in breast cancer cells (Laezza
et al., 2012), this is the first time a Wnt inhibiting role for
THC has been described in innate immune cells, demonstrating
the strength of kinome profiling for identification of novel
therapeutic targets.
Our data suggest that aside the aforementioned analgesic
properties, the use of medical marijuana may provide additional
benefits in patients with chronic inflammatory disorders. One of
such diseases might be chronic pancreatitis (CP), a progressive
fibroinflammatory disorder resulting in damage and scarring
of pancreatic tissue, eventually leading to loss of function
(Raimondi et al., 2010). Abdominal pain, the predominant
symptom in CP, is in the early stage of the disease largely
attributed to the interaction of inflammatory cells and neurons
within the pancreas. The extensive pancreatic fibrosis found
in CP is thought to be mediated by pancreatic stellate cells,
activated by (necro)inflammation and/or alcohol (Witt et al.,
2007). While the underlying immune pathology is not yet fully
elucidated, it is clear that both the innate and adaptive immune
response play a central role in the development of CP (Xue
et al., 2014). In particular, increased numbers of mononuclear
myeloid cells (i.e., monocytes, macrophages) as well as T cells
are observed in CP and its stromal compartment (Jaskiewicz
et al., 2003) and in animal models, suppression of T cells was
shown to alleviate pancreatitis (Yamada et al., 2001). All things
considered, a central role of inflammation in the pathogenesis of
CP is implied. While we have previously shown that levels of the
proinflammatory cytokine TNFα are increased in patients with
CP, we did not observe an effect on Namisol R© intake on serum
cytokine levels (Utomo et al., 2015). The current study suggests
that Namisol R© may provide acute anti-inflammatory relief
through down modulation of innate and adaptive inflammatory
signaling. One potential mechanism of inflammatory signaling
reduction by cannabinoids might be through the downregulation
of the immune receptors recognizing the pathogen-associated
molecular patterns (PAMPs), such as the LPS receptor Toll
like receptor (TLR) 4 (Xu et al., 2007). Indeed, suppression
of TLR4 mediated inflammatory signals by cannabinoids has
been shown in many studies (reviewed in McCoy and Kathleen,
2016). However, anecdotal evidence in our study also suggests
that mTOR-S6 signaling may increase in immunocytes upon
prolonged exposure to THC. It is conceivable that repeated
short term inhibition of signaling results in a compensatory
upregulation of said pathway (see Supplementary Figure S5),
arguing for caution in long-term use of such treatments. While
not common, several case reports of THC-induced pancreatitis
have been reported (Wargo et al., 2007; Mikolaševic´ et al., 2013;
Kayar et al., 2014), indicating that while short term THC use may
be beneficial due to its anti-inflammatory properties, care should
be taken with prolonged cannabis use.
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